Rua Bioscience Ltd.NZX: RUA

RUA: FY25 revenue soared and losses narrowed, but further capital is needed to fuel global growth

· Issued by Rua Bioscience Ltd.

Revenue surged nearly sixfold to $1.90m in FY25, with losses sharply reduced and strong sales momentum across five international markets. Additional capital is needed to sustain growth, with further expansion expected in FY26.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Rua Bioscience

All Rua Bioscience news releases